Michael Adashek, DO
Hematology/oncology in Towson, MD
About Dr. Michael Adashek
Dr. Michael Adashek is a physician specializing in hematology/oncology practicing in Towson, MD, a graduate of West Virginia School of Osteopathic Medicine (2017). Affiliated with Greater Baltimore Medical Center, University of Maryland Medical Center, University of MD St Joseph Medical Center. Treated 343 Medicare patients in 2024.
| Specialty | Hematology/oncologyOther hematology/oncology doctors in Towson |
|---|---|
| Credentials | DO |
| Education | West Virginia School of Osteopathic Medicine, 2017CMS Doctors and Clinicians |
| Gender | Male |
| NPI number | 1972037661National Provider Identifier (CMS NPPES), issued April 2017 |
| Medicare | Enrolled in Medicare; accepts Medicare assignment (the Medicare-approved amount as full payment)CMS Doctors and Clinicians |
Where Dr. Michael Adashek practices
- Chesapeake Urology Associates, LLC 6535 N Charles St, Suite 500, Towson, MD 21204 (410) 825-5454 · Directions · group of 179 clinicians
Addresses from CMS Doctors and Clinicians (Medicare enrollment). Call before visiting: a clinician may not see patients at every listed address.
Dr. Michael Adashek's specialties and state licenses
| Specialty (NPPES) | License |
|---|---|
| Hematology & Oncology Primary | MD H96426 |
As reported by the clinician to the NPPES registry. Confirm a license and any disciplinary history with the state medical or licensing board.
Hospital affiliations of Dr. Michael Adashek
- Greater Baltimore Medical CenterHospital · Baltimore, MD
- University of Maryland Medical CenterHospital · Baltimore, MD
- University of MD St Joseph Medical CenterHospital · Towson, MD
CMS Facility Affiliation data: facilities where the clinician bills Medicare.
Dr. Michael Adashek's Medicare patients and services (2024)
Most frequent services
| Service | Times | Avg. Medicare allowed |
|---|---|---|
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 441 | $16.83 |
| Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more | 406 | $112.01 |
| Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more | 168 | $166.99 |
| Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more | 67 | $73.75 |
| New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more | 60 | $204.14 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 36 | $176.57 |
| New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more | 28 | $136.66 |
| Prolonged hospital inpatient or observation care evaluation and management service(s) beyond the total time for the primary service (when the primary service has been selected using time on the date of the primary service); each additional 15 minutes by th | 25 | $30.83 |
Common conditions among these patients
Medicare Part B fee-for-service claims only (CMS Medicare Physician & Other Practitioners, 2024). Patients with private insurance or Medicare Advantage are not counted; small counts are suppressed by CMS. This describes the patients, not the quality of care.
Dr. Michael Adashek's Medicare quality score (MIPS 2024)
The Merit-based Incentive Payment System scores clinicians who bill Medicare. Reported as group. Source: CMS Care Compare, PY 2024 clinician public reporting.
Payments from drug and device companies to Dr. Michael Adashek (2025)
$2,060.88 in 92 general payments reported in 2025.
| Type | Payments | Amount |
|---|---|---|
| Food and beverage | 92 | $2,060.88 |
Paying companies: Janssen Biotech, Inc. ($342.09), Bayer HealthCare Pharmaceuticals Inc. ($195.99), Dendreon Pharmaceuticals LLC ($191.13), Ferring Pharmaceuticals Inc. ($154.77), GlaxoSmithKline, LLC. ($112.57), Sumitomo Pharma America, Inc. ($104.94).
Reported by companies under the federal Open Payments program (CMS, program year 2025). A payment, such as a meal at an educational event, does not mean wrongdoing; clinicians can dispute records with CMS.
Questions about Dr. Michael Adashek
What kind of clinician is Dr. Michael Adashek?
Dr. Michael Adashek is listed as a physician specializing in hematology/oncology.
Where does Dr. Michael Adashek practice?
Chesapeake Urology Associates, LLC at 6535 N Charles St, Suite 500, Towson, MD 21204.
What is the office phone number for Dr. Michael Adashek?
The listed office number is (410) 825-5454. Call to confirm availability and whether new patients are accepted.
What is the NPI number of Dr. Michael Adashek?
The National Provider Identifier is 1972037661.
Does Dr. Michael Adashek accept Medicare?
Yes. CMS lists this clinician as accepting Medicare assignment. Confirm your plan with the office.
Which hospitals is Dr. Michael Adashek affiliated with?
Greater Baltimore Medical Center, University of Maryland Medical Center, University of MD St Joseph Medical Center.
Where did Dr. Michael Adashek go to medical school?
West Virginia School of Osteopathic Medicine, graduating in 2017.
Where this information comes from
| CMS Doctors and Clinicians | Name, specialty, education, Medicare enrollment and practice addresses.Centers for Medicare & Medicaid Services, national downloadable file (2026) |
|---|---|
| NPPES NPI registry | NPI, specialties (taxonomy) and state licenses.CMS National Plan and Provider Enumeration System; record updated 2025-03-18 |
| Facility affiliations | Hospitals and other facilities.CMS Doctors and Clinicians facility affiliation file; names from CMS Provider of Services |
| Medicare utilization | Patients, services and conditions.CMS Medicare Physician & Other Practitioners, 2024 |
| MIPS | Quality payment program scores.CMS clinician public reporting, PY 2024 |
| Open Payments | Payments from drug and device companies.CMS Open Payments, program year 2025 |
Information is public record and may lag behind changes. Clinicians update it through NPPES and Medicare PECOS. See something wrong? Tell us.